These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21476870)

  • 1. In vitro conversion and seeded fibrillization of posttranslationally modified prion protein.
    Stöhr J; Elfrink K; Weinmann N; Wille H; Willbold D; Birkmann E; Riesner D
    Biol Chem; 2011 May; 392(5):415-21. PubMed ID: 21476870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural transition of the prion protein into its pathogenic conformation is induced by unmasking hydrophobic sites.
    Leffers KW; Schell J; Jansen K; Lucassen R; Kaimann T; Nagel-Steger L; Tatzelt J; Riesner D
    J Mol Biol; 2004 Nov; 344(3):839-53. PubMed ID: 15533449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
    Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
    Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous and BSE-prion-seeded amyloid formation of full length recombinant bovine prion protein.
    Panza G; Stöhr J; Dumpitak C; Papathanassiou D; Weiss J; Riesner D; Willbold D; Birkmann E
    Biochem Biophys Res Commun; 2008 Sep; 373(4):493-7. PubMed ID: 18585368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the cellular prion protein with raft-like lipid membranes.
    Elfrink K; Nagel-Steger L; Riesner D
    Biol Chem; 2007 Jan; 388(1):79-89. PubMed ID: 17214553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential solubility of prions is associated in manifold phenotypes.
    Kuczius T; Karch H; Groschup MH
    Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization.
    Kazlauskaite J; Sanghera N; Sylvester I; Vénien-Bryan C; Pinheiro TJ
    Biochemistry; 2003 Mar; 42(11):3295-304. PubMed ID: 12641461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion-protein-specific aptamer reduces PrPSc formation.
    Proske D; Gilch S; Wopfner F; Schätzl HM; Winnacker EL; Famulok M
    Chembiochem; 2002 Aug; 3(8):717-25. PubMed ID: 12203970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
    Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
    Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine sulfoxides on PrPSc: a prion-specific covalent signature.
    Canello T; Engelstein R; Moshel O; Xanthopoulos K; Juanes ME; Langeveld J; Sklaviadis T; Gasset M; Gabizon R
    Biochemistry; 2008 Aug; 47(34):8866-73. PubMed ID: 18680312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scrapie prion protein structural constraints obtained by limited proteolysis and mass spectrometry.
    Sajnani G; Pastrana MA; Dynin I; Onisko B; Requena JR
    J Mol Biol; 2008 Sep; 382(1):88-98. PubMed ID: 18621059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembly of recombinant prion protein of 106 residues.
    Baskakov IV; Aagaard C; Mehlhorn I; Wille H; Groth D; Baldwin MA; Prusiner SB; Cohen FE
    Biochemistry; 2000 Mar; 39(10):2792-804. PubMed ID: 10704232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-translational hydroxylation at the N-terminus of the prion protein reveals presence of PPII structure in vivo.
    Gill AC; Ritchie MA; Hunt LG; Steane SE; Davies KG; Bocking SP; Rhie AG; Bennett AD; Hope J
    EMBO J; 2000 Oct; 19(20):5324-31. PubMed ID: 11032800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.